The 19th St Gallen Breast Oncology Conference begins on 12 March 2025 : "Should we combine adjuvant drugs that were tested in isolation in phase 3 trials?"
Our paper with Vinay Prasad is now published in the Journal of Cancer Policy – and it couldn’t be more timely!
Our new paper, entitled “Adding Adjuvant Drugs From Distinct Breast Cancer Trials”, co-authored with Vinay Prasad, is out in the Journal of Cancer Policy today ! The full paper is available here (pre-proof).
This couldn’t be more timely, as the 19th St. Gallen International Breast Cancer Conference 2025 begins in 3 days – on 12th March in Vienna. St Gallen is an internationally renowned medical symposium, held biennially, focusing on the latest evidence-based strategies for breast cancer treatment. It gathers global experts to establish consensus guidelines influencing clinical practice worldwide.
Here is the tweetorial I posted on X to explain our paper:
Due to the high number needed to treat for each individual drug in this setting and the lack of evidence for the combination, for most patients, it’s just a toxic placebo cocktail with a hefty price tag!